Articles From: Blue Water Announces Stock Dividend to Bluegrass Pipeline Announces Extension of Open Season until January 17


2014/1/27
CANTON, Ga., Jan.
Sign-up for Blue Water Announces Stock Dividend investment picks
CANTON, Ga., Nov.
Sign-up for Blue Water Announces the Acquisition of a St. Maarten Business License investment picks
2014/1/14
CANTON, Ga., Jan.
Sign-up for Blue Water Anticipates Record Year in Delivering Shareholder Value investment picks
2014/4/3
CANTON, Ga., April 3, 2014 (GLOBE NEWSWIRE) -- Blue Water Global Group, Inc. (OTCBB:BLUU) announces that it has repaid early and in full its second Convertible Promissory Note owed to Asher Enterprises, Inc. (" Asher ") with a maturity date of August 12, 2014.
Sign-up for Blue Water Continues to Pay Off Early-Stage Convertible Debt investment picks
2014/3/4
CANTON, Georgia, March 4, 2014 (GLOBE NEWSWIRE) -- Blue Water Global Group, Inc. (OTCBB:BLUU) announces that it has retained Another Ard Production (" AAP "), a full-service architectural firm, to complete the design, engineering and permitting process for one of its planned Blue Water Bar & Grill™ restaurants on the island of St.
Sign-up for Blue Water Engages Prestigious Architectural Firm investment picks
2014/1/15
CANTON, Ga., Jan.
Sign-up for Blue Water Enters Into LOI for Distillation of Its Own Privately Labeled Rums investment picks
http://media.marketwire.com/attachments/201104/61410_qualitystocks-300dpi.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1074246&ProfileId=051205&sourceType=1 SCOTTSDALE, AZ --
Sign-up for Blue Water Global Group, Inc. CEO Featured in Exclusive QualityStocks Interview investment picks
2014/3/12
CANTON, Ga., March 12, 2014 (GLOBE NEWSWIRE) -- Blue Water Global Group, Inc. (OTCBB:BLUU) announces the successful realization of the first set of significant milestones towards developing and profiting from its Stream Flow Media, Inc. (" Stream Flow ") equity investment.
Sign-up for Blue Water Investment Achieves Significant Milestone investment picks
2014/2/10
CANTON, Ga., Feb.
Sign-up for Blue Water on Pace With Its Blue Water Bar & Grill(TM) Restaurants investment picks
2014/3/14
CANTON, Ga., March 14, 2014 (GLOBE NEWSWIRE) -- Blue Water Global Group, Inc. (OTCBB:BLUU) unveiled today its bottle design and product name for its flagship high-end luxury rum, Blue Water Ultra Premium Rum™. Images of the Blue Water Ultra Premium Rum™ bottle may be found on Blue Water's website ( www.bluewaterglobalgroup.com/blue-water-premium-rums ) or through its Facebook and Twitter pages.
Sign-up for Blue Water Unveils Bottle Design for Its Ultra Premium Rum investment picks
2013/12/2
bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 HGB-205 study in France and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation.
Sign-up for bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia investment picks
2014/3/27
bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study (HGB-204) in the United States and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation.
Sign-up for bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia investment picks
2013/10/28
bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject in its phase 2/3 childhood cerebral adrenoleukodystrophy (CCALD) study, Starbeam (ALD-102) has undergone infusion with bluebird bio’s Lenti-D drug product in an autologous hematopoietic stem cell transplantation.
Sign-up for bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD investment picks
bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, announced today that James Mandell, M.D. has joined the company’s board of directors.
Sign-up for bluebird bio Appoints Dr James Mandell to its Board of Directors investment picks
2013/12/26
bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the company was recently added to the NASDAQ Biotechnology Index (Nasdaq: NBI) effective prior to the market open on December 23, 2013.
Sign-up for bluebird bio Joins the NASDAQ Biotechnology Index investment picks
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the company has been added to the Russell 2000 ® , Russell 3000 ® and Russell Global ® Indexes as part of Russell Investments’ third quarter IPO additions that took place after the market closed on September 30, 2013.
Sign-up for bluebird bio Joins the Russell 2000® Index investment picks
2013/8/14
bluebird bio, Inc. (Nasdaq: BLUE) , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended June 30, 2013.
Sign-up for bluebird bio Reports Fiscal Second Quarter 2013 Financial Results investment picks
2013/11/14
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended September 30, 2013.
Sign-up for bluebird bio Reports Fiscal Third Quarter 2013 Financial Results investment picks
2014/3/5
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2013.
Sign-up for bluebird bio Reports Fiscal Year End 2013 Financial Results investment picks
2013/8/27
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has been named a 2014 Technology Pioneer , a prestigious award from the World Economic Forum honoring the world’s most innovative technology start-ups.
Sign-up for bluebird bio Selected As A 2014 Technology Pioneer By The World Economic Forum investment picks
2013/11/27
bluebird bio, Inc. (Nasdaq:BLUE) announces that management will present at the Deutsche Bank BioFEST Conference to be held December 2 - 3, 2013 at the Four Seasons Hotel, Boston, MA.
Sign-up for bluebird bio to Present at Deutsche Bank BioFEST Conference investment picks
2013/9/4
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Morgan Stanley Healthcare Conference to be held September 9 - 11, 2013 at the Grand Hyatt Hotel, New York, NY.
Sign-up for bluebird bio to Present at Morgan Stanley Global Healthcare Conference investment picks
2014/2/26
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Cowen and Company 34 th Annual Health Care Conference to be held March 2 - 5, 2014 at the Boston Marriott Copley Place Hotel, Boston, MA.
Sign-up for bluebird bio to Present at the Cowen and Company Health Care Conference investment picks
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the 32 nd Annual J.P.Morgan Healthcare Conference to be held January 13 - 16, 2014 at the Westin St Francis Hotel, San Francisco, CA.
Sign-up for bluebird bio to Present at the J.P.Morgan Healthcare Conference investment picks
2014/2/5
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Leerink Global Healthcare Conference to be held February 12 - 13, 2014 at the Waldorf Astoria Hotel, New York, NY.
Sign-up for bluebird bio to Present at the Leerink Global Healthcare Conference investment picks
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Securities Life Sciences Conference to be held August 13 - 14, 2013 at the Le Parker Meridien Hotel, New York, NY, and at the Canaccord Genuity Healthcare Conference to be held August 14 - 15, 2013 at the Intercontinental Hotel, Boston, MA.
Sign-up for bluebird bio to Present at Two Upcoming Conferences investment picks
2013/10/2
BlueFire Equipment Corporation (OTCQB: BLFR) revealed today that it has filed a provisional patent application for its proprietary offshore production technology at the United States Patent and Trademark Office (USPTO). The filing is currently under review by a USPTO examiner.
Sign-up for BlueFire Equipment Corporation Files Patent with USPTO investment picks
BlueFire Equipment Corporation (OTCQB: BLFR) announced today that it has been in discussions with an oil major to develop technology that may prove essential for producing oil from offshore wells under extremely high heat and pressure.
Sign-up for BlueFire Equipment Corporation in Talks with Oil Major investment picks
2013/10/3
IRVINE, Calif., Oct.
Sign-up for BlueFire Renewables Adds New Revenue Source to Fulton Facility investment picks
Bluegrass Pipeline LLC, a joint venture between Williams (NYSE:WMB) and Boardwalk Pipeline Partners, LP (NYSE: BWP) (Boardwalk), today announced that it is extending its binding Open Season until Jan.
Sign-up for Bluegrass Pipeline Announces Extension of Open Season until January 17 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Blue Water Announces Stock Dividend to Bluegrass Pipeline Announces Extension of Open Season until January 17
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity